Skip to main content

bbo-10203

Generic: RAS/PI3K-alpha Interaction Inhibitor BBO-10203·Code: BBO-10203

bbo-10203: 3 clinical trials tracked.

bbo-10203 evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about bbo-10203, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (3)

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers

NCT06917079Registry updated 2026-06-02·Phase 1
Recruiting

Primary endpoint: Incidence and severity of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)

Interventionalopen665 targetStarted 2025-03Completion 2029-0917 sites · Australia, United StatesTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

NCT06625775Registry updated 2026-10-01·Phase 1
Recruiting

Primary endpoint: Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BBO-10203 as a single agent

Interventionalopen392 targetStarted 2024-10Completion 2028-1144 sites · Australia, Brazil, France, South Korea…TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study

NCT06343402Registry updated 2026-09-03·Phase 1
Recruiting

Primary endpoint: Adverse Events

Interventionalopen350 targetStarted 2024-05Completion 2031-0938 sites · Australia, Canada, Denmark, Spain…TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)